Irbesartán/Hidroclorotiazida Normon (Hydrochlorothiazide, Irbesartan)

• Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower elevated blood pressure.
• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Stage 1 hypertension: helps achieve recommended blood‑pressure goals when monotherapy is insufficient.
• Stage 2 hypertension: used as part of combination therapy for patients needing stronger pressure control.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined actions lower peripheral vascular resistance and plasma volume, resulting in reduced arterial pressure.

The following adverse reactions have been reported with the fixed‑dose combination of irbesartan and hydrochlorothiazide.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache, often mild to moderate in intensity.
• Fatigue or general weakness.
• Increased urinary frequency or volume.
• Electrolyte disturbances such as low potassium or sodium.
• Mild gastrointestinal discomfort, including nausea.

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance requiring medical attention.
• Hyperkalemia, particularly in patients with renal impairment.
• Angioedema or swelling of the face, lips, or throat.
• Acute kidney injury or significant rise in serum creatinine.
• Severe hypotension leading to syncope.
• Allergic reactions such as rash, pruritus, or urticaria.

• Before initiating therapy, clinicians should consider several safety measures.
• Monitor blood pressure regularly: adjust dose based on response.
• Assess renal function: check serum creatinine and eGFR before and during treatment.
• Check electrolytes: especially potassium and sodium levels.
• Use caution in hepatic impairment: dose adjustments may be needed.
• Avoid in patients with known hypersensitivity to either component.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/hydrochlorothiazide may interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes or renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Lithium: increased lithium levels and toxicity.
• ACE inhibitors or other ARBs: additive renal effects.
• NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause excessive blood‑pressure lowering.
• CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan levels.
• Antidiabetic agents: diuretic‑induced changes in glucose control.
• Anticoagulants: potential for altered INR with thiazide‑induced volume changes.